278 related articles for article (PubMed ID: 27072583)
1. Osteoprotegerin rich tumor microenvironment: implications in breast cancer.
Goswami S; Sharma-Walia N
Oncotarget; 2016 Jul; 7(27):42777-42791. PubMed ID: 27072583
[TBL] [Abstract][Full Text] [Related]
2. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
Vitovski S; Phillips JS; Sayers J; Croucher PI
J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
[TBL] [Abstract][Full Text] [Related]
3. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
5. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
6. Unbalanced Vitreous Levels of Osteoprotegerin, RANKL, RANK, and TRAIL in Proliferative Diabetic Retinopathy.
Abu El-Asrar AM; Ahmad A; Alam K; Bittoun E; Siddiquei MM; Mohammad G; Mousa A; De Hertogh G; Opdenakker G
Ocul Immunol Inflamm; 2018; 26(8):1248-1260. PubMed ID: 28914577
[TBL] [Abstract][Full Text] [Related]
7. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors.
Fili S; Karalaki M; Schaller B
Cancer Lett; 2009 Sep; 283(1):10-9. PubMed ID: 19201081
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin: multiple partners for multiple functions.
Baud'huin M; Duplomb L; Teletchea S; Lamoureux F; Ruiz-Velasco C; Maillasson M; Redini F; Heymann MF; Heymann D
Cytokine Growth Factor Rev; 2013 Oct; 24(5):401-9. PubMed ID: 23827649
[TBL] [Abstract][Full Text] [Related]
10. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
Nyambo R; Cross N; Lippitt J; Holen I; Bryden G; Hamdy FC; Eaton CL
J Bone Miner Res; 2004 Oct; 19(10):1712-21. PubMed ID: 15355567
[TBL] [Abstract][Full Text] [Related]
11. The Role of Osteoprotegerin and Its Ligands in Vascular Function.
Rochette L; Meloux A; Rigal E; Zeller M; Cottin Y; Vergely C
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736365
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiological roles of osteoprotegerin (OPG).
Reid P; Holen I
Eur J Cell Biol; 2009 Jan; 88(1):1-17. PubMed ID: 18707795
[TBL] [Abstract][Full Text] [Related]
13. Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.
Deligiorgi MV; Panayiotidis MI; Griniatsos J; Trafalis DT
Clin Exp Metastasis; 2020 Feb; 37(1):13-30. PubMed ID: 31578655
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin is expressed in colon carcinoma cells.
Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.
McGonigle JS; Giachelli CM; Scatena M
Angiogenesis; 2009; 12(1):35-46. PubMed ID: 19105036
[TBL] [Abstract][Full Text] [Related]
17. Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.
Zinonos I; Labrinidis A; Lee M; Liapis V; Hay S; Ponomarev V; Diamond P; Findlay DM; Zannettino AC; Evdokiou A
J Bone Miner Res; 2011 Mar; 26(3):630-43. PubMed ID: 20818644
[TBL] [Abstract][Full Text] [Related]
18. Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.
Higgs JT; Jarboe JS; Lee JH; Chanda D; Lee CM; Deivanayagam C; Ponnazhagan S
Mol Cancer Res; 2015 May; 13(5):819-27. PubMed ID: 25636966
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.
Rachner TD; Benad P; Rauner M; Goettsch C; Singh SK; Schoppet M; Hofbauer LC
J Cell Biochem; 2009 Sep; 108(1):106-16. PubMed ID: 19544400
[TBL] [Abstract][Full Text] [Related]
20. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment.
Lamoureux F; Moriceau G; Picarda G; Rousseau J; Trichet V; Rédini F
Biochim Biophys Acta; 2010 Jan; 1805(1):17-24. PubMed ID: 19733222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
